Core Viewpoint - The company, Greechuang Tongqiao (02190.HK), anticipates significant growth in its financial performance for the year ending December 31, 2025, with net profit and revenue projections showing substantial increases compared to the previous year [1] Financial Performance - The expected net profit attributable to equity holders is projected to exceed RMB 240 million, representing a year-on-year increase of approximately 139.4% from RMB 100 million for the year ending December 31, 2024 [1] - The anticipated group revenue is expected to surpass RMB 1.05 billion, reflecting a year-on-year growth of about 34.6% from RMB 780 million for the year ending December 31, 2024 [1] Growth Drivers - The significant improvement in performance is driven by three main factors: 1. Strong domestic sales growth of several flagship products, including the Qilin blood flow guiding device, neurovascular guide wires, UltraFree drug-eluting PTA balloon catheters, and Swan venous endovenous radiofrequency closure catheters [1] 2. Successful market expansion in multiple regions, leading to international sales growth of over 100% year-on-year [1] 3. Relatively stable gross margins combined with continuously improving operational efficiency [1]
归创通桥(02190.HK)：预计2025年度净利润将超过2.4亿元 同比增长约139.4%